Mark A. Beck receives restricted stock grant at Accendra Health (ACH)
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Beck Mark A reported acquisition or exercise transactions in this Form 4 filing.
Accendra Health Inc. director Mark A. Beck received a grant of 31,191 shares of common stock as equity compensation. The restricted stock was awarded at no cash cost to him and increases his direct holdings to 71,259 shares.
According to the terms, the restricted stock vests on the earlier of one year from the grant date or the date of the next annual meeting that is at least 50 weeks after the grant date. Until vesting, these shares are subject to forfeiture conditions typically linked to continued board service.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Beck Mark A
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 31,191 | $0.00 | -- |
Holdings After Transaction:
Common Stock — 71,259 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Restricted stock grant: 31,191 shares
Post-transaction holdings: 71,259 shares
Grant price: $0.00 per share
3 metrics
Restricted stock grant
31,191 shares
Common Stock awarded to director on May 14, 2026
Post-transaction holdings
71,259 shares
Total common shares directly held after grant
Grant price
$0.00 per share
Reported transaction price for restricted stock award
Key Terms
Restricted stock grant, vests, annual meeting
3 terms
Restricted stock grant financial
"Restricted stock grant which vests the earlier of (i) one year from the grant date"
A restricted stock grant is an award of company shares given to an employee or executive that cannot be sold or transferred until certain conditions are met, such as staying with the company for a set time or hitting performance goals. For investors, it signals how the company ties pay to future performance and can affect the number of shares outstanding and management’s incentives—think of it as a wrapped gift you only keep once you meet the requirements.
vests financial
"Restricted stock grant which vests the earlier of (i) one year from the grant date"
annual meeting financial
"and (ii) the date of the next annual meeting that is at least 50 weeks"
A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.
FAQ
What insider transaction did Accendra Health (ACH) report for Mark A. Beck?
Accendra Health reported that director Mark A. Beck received a grant of 31,191 shares of common stock. This is a restricted stock award given as equity compensation, not an open-market purchase, and it increases his direct holdings to 71,259 shares.
Was the Accendra Health (ACH) stock grant to Mark A. Beck a purchase or a compensation award?
The transaction was a compensation award, classified as a grant or other acquisition, not a market purchase. The shares were issued at a stated price of $0.00 per share as restricted stock, reflecting typical director equity compensation rather than an investment-driven buy.
What are the vesting terms of Mark A. Beck’s restricted stock in Accendra Health (ACH)?
The restricted stock vests on the earlier of one year from the grant date or the date of the next annual meeting at least 50 weeks after the grant date. Until vesting, the shares remain restricted and can generally be forfeited if service conditions are not satisfied.
Does Accendra Health (ACH) Form 4 indicate any stock sales by Mark A. Beck?
This Form 4 does not report any stock sales by Mark A. Beck. It only shows an acquisition of 31,191 restricted common shares as a grant, with no open-market sale, disposition, or derivative exercise activity disclosed in the summarized data.